According to a new report, published by KBV research, The Global Facial Injectable Market size is expected to reach $22.5 billion by 2029, rising at a market growth of 10.1% CAGR during the forecast period.
The Hospitals market is showcasing a CAGR of 10.8% during (2023 - 2029). This is because hospital healthcare infrastructure has increased. People are inclined to go to hospitals for aesthetic treatments due to the convenience of doing diagnostic imaging immediately following a doctor's consultation. Growth in the hospital sector is attributed to the availability of experienced surgeons and a surplus of necessary equipment.
The Botulinum Toxin Type A market is leading the Global Facial Injectable Market by Product in 2022 thereby, achieving a market value of $11.3 billion by 2029. Women in their middle years widely use injectables and fillers like botulinum toxin type A to combat the signs of ageing. This is explained by the increase in the use of BoNTA in cosmetic (esthetic) treatments, improvements in face look, and the substance's potency in eradicating age indications.
The Lip Augmentation market has shown the high growth rate of 9.8% during (2023 - 2029). Lip augmentation is a cosmetic approach used to increase the volume of lips by using fillers that can be either temporary or permanent. The demand for lip augmentation is expanding due to the rising demand for cosmetic surgery among both older and younger demographics. Major drivers of this expansion include technological advances and hiring more cosmetic physicians.
The North America market dominated the Global Facial Injectable Market by Region in 2022 thereby, achieving a market value of $8.5 billion by 2029. The Europe market is anticipated to grow at a CAGR of 9.4% during (2023 - 2029). Additionally, The Asia Pacific market would witness a CAGR of 11.1% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/facial-injectable-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Suneva Medical, Inc., Medytox Inc., Sinclair Pharma Ltd., Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group), Anika Therapeutics, Inc., Prollenium Medical Technologies Inc., Galderma S.A., and Allergan PLC (AbbVie, Inc.).
By End-use
By Product
By Application
By Geography
Companies Profiled
Unique Offerings 
